Abstract
Replication-deficient adenoviruses are considered as gene delivery vectors for the genetic treatment of a variety of diseases. The ability of such vectors to mediate efficient expression of therapeutic genes in a broad spectrum of dividing and non-dividing cell types constitutes an advantage over alternative gene transfer vectors. However, this broad tissue tropism may also turn disadvantageous when genes encoding potentially harmful proteins (e.g. cytokines, toxic proteins) are expressed in surrounding normal tissues. Therefore, specific restrictions of the viral tropism would represent a significant technological advance towards safer and more efficient gene delivery vectors, in particular for cancer gene therapy applications. In this review, we summarize various strategies used to selectively modify the natural tropism of recombinant adenoviruses. The advantages, limitations and potential impact on gene therapy operations of such modified vectors are discussed.
Keywords: Adenovirus Vectors, TROPISM, Fiber Protein, Monoclonal antibody
Current Gene Therapy
Title: Transductional Targeting with Recombinant Adenovirus Vectors
Volume: 2 Issue: 3
Author(s): Valerie Legrand, Philippe Leissner, Arend Winter, Majid Mehtali and Monika Lusky
Affiliation:
Keywords: Adenovirus Vectors, TROPISM, Fiber Protein, Monoclonal antibody
Abstract: Replication-deficient adenoviruses are considered as gene delivery vectors for the genetic treatment of a variety of diseases. The ability of such vectors to mediate efficient expression of therapeutic genes in a broad spectrum of dividing and non-dividing cell types constitutes an advantage over alternative gene transfer vectors. However, this broad tissue tropism may also turn disadvantageous when genes encoding potentially harmful proteins (e.g. cytokines, toxic proteins) are expressed in surrounding normal tissues. Therefore, specific restrictions of the viral tropism would represent a significant technological advance towards safer and more efficient gene delivery vectors, in particular for cancer gene therapy applications. In this review, we summarize various strategies used to selectively modify the natural tropism of recombinant adenoviruses. The advantages, limitations and potential impact on gene therapy operations of such modified vectors are discussed.
Export Options
About this article
Cite this article as:
Legrand Valerie, Leissner Philippe, Winter Arend, Mehtali Majid and Lusky Monika, Transductional Targeting with Recombinant Adenovirus Vectors, Current Gene Therapy 2002; 2 (3) . https://dx.doi.org/10.2174/1566523023347823
DOI https://dx.doi.org/10.2174/1566523023347823 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Emerging Features in the Regulation of MMP-9 Gene Expression for the Development of Novel Molecular Targets and Therapeutic Strategies
Current Drug Targets - Inflammation & Allergy Inflammation and Antiangiogenesis in Cancer
Current Medicinal Chemistry Postmenopausal Hormone Therapy
Current Women`s Health Reviews Novel Glitazones with Diverse Peroxisome Proliferator Activated Receptor Modulatory Potential
Current Bioactive Compounds Meet Our Editorial Board Member
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Modulators of Acetylcholinesterase Activity: From Alzheimer's Disease to Anti-Cancer Drugs
Current Medicinal Chemistry Hyaluronidase Inhibitors: A Biological and Therapeutic Perspective
Current Medicinal Chemistry Paraneoplastic Pemphigus: Autoimmune-Cancer Nexus in the Skin
Anti-Cancer Agents in Medicinal Chemistry α-Lipoic Acid Supplementation: A Tool for Obesity Therapy?
Current Pharmaceutical Design Impaired Autophagy Mediates Resistance to Low-Dose Metronomic Cyclophosphamide Chemotherapy
Clinical Cancer Drugs Human Aurora / Ipl1p Related Kinases
Current Genomics Oxygen Sensing, Cardiac Ischemia, HIF-1α and Some Emerging Concepts
Current Cardiology Reviews Telomeres and Thyroid Cancer
Current Genomics Intracellular Drug Delivery: Mechanisms for Cell Entry
Current Pharmaceutical Design 1-O-Octadecyl-2-O-Methylglycero-3-phosphocholine (Edelfosine) and Cancer Cell Invasion: A Short Review
Anti-Cancer Agents in Medicinal Chemistry Imaging of Integrins as Biomarkers for Tumor Angiogenesis
Current Pharmaceutical Design The Role of Connexins in Carcinogenesis: Review of Current Knowledge
Current Signal Transduction Therapy Molecules to Selectively Target Receptors for Treatment of Pain and Neurogenic Inflammation
Recent Patents on Inflammation & Allergy Drug Discovery Editorial [Hot Topic: Cancer Vaccine and Immunotherapy (Executive Editor: Farid Saleh)]
Current Pharmaceutical Design Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs
Current Cancer Drug Targets